Serum metabolomic profiling correlated with ISS and clinical outcome for multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation
Open Access
- 1 May 2021
- journal article
- research article
- Published by Elsevier in Experimental Hematology
- Vol. 97, 79-88.e8
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survivalEuropean Journal of Haematology, 2018
- Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients – a pilot studyLeukemia & Lymphoma, 2016
- Myeloma today: Disease definitions and treatment advancesAmerican Journal of Hematology, 2015
- Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression–Related DeathJournal of Clinical Oncology, 2014
- A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancerCancer Letters, 2014
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia, 2013
- Proton NMR-Based Metabolite Analyses of Archived Serial Paired Serum and Urine Samples from Myeloma Patients at Different Stages of Disease Activity Identifies Acetylcarnitine as a Novel Marker of Active DiseasePLOS ONE, 2013
- Metabolomic NMR Fingerprinting to Identify and Predict Survival of Patients with Metastatic Colorectal CancerCancer Research, 2012
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005